Coegin Pharma

3.39 SEK

-7.12 %

Less than 1K followers

COEGIN

Nordic SME

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

-7.12 %

-12.85 %

-20.42 %

-23.65 %

-46.36 %

-18.51 %

-71.37 %

-86.30 %

-89.34 %

Coegin Pharma is a Swedish biotechnology company in commercial phase, developing science-based innovations for hair and skin. The company's patented ingredient for hair growth is now available in products sold through selected partners. A peptide for natural skin pigmentation is also in development with a planned launch in the near future. Coegin Pharma is headquartered in Lund.

Market cap

96.92M SEK

Turnover

407.36K SEK

Revenue

79K

EBIT %

-25,888.61 %

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

21.5

2026

Interim report Q1'26

21.5

2026

General meeting '26

19.8

2026

Interim report Q2'26

All

Press releases

ShowingAll content types

Regulatory press release4/29/2026, 12:00 PM

Coegin Pharma AB publishes Annual Report for 2025

Regulatory press release4/20/2026, 7:20 AM

Notice of annual general meeting in Coegin Pharma AB (publ)

Press release4/16/2026, 12:53 PM

Coegin Pharma expands commercial strategy with own-brand distribution model - launches VEXIENNE®

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release3/26/2026, 1:25 PM

Coegin Pharma's management acquires shares in the company

Press release3/4/2026, 1:30 PM

Coegin Pharma receives first purchase order for new scalp serum

Press release3/2/2026, 10:30 AM

Coegin Pharma accelerates Follicopeptide® portfolio expansion with a new high-performance scalp serum

Regulatory press release2/26/2026, 1:30 PM

Coegin Pharma AB (publ) publishes its year-end report for 2025

Regulatory press release2/19/2026, 5:40 PM

Coegin Pharma carries out directed issues totalling approx. SEK 12.1 million and strengthens the Company's liquidity position

Press release1/2/2026, 8:30 AM

Coegin Pharma provides an operational and strategic update

Press release12/22/2025, 12:30 PM

Coegin Pharma appoints worldleading pigmentation and hair-biology expert Professor Desmond J. Tobin as Scientific Advisor

Press release12/19/2025, 8:25 AM

Coegin Pharma completes first delivery of Follicopeptide products to Hårklinikken

Press release12/12/2025, 10:50 AM

Coegin Pharma delivers first commercial batch of Follicopeptide products to Gents

Regulatory press release11/27/2025, 8:45 AM

Coegin Pharma's Nomination Committee appointed for the 2026 Annual General Meeting

Regulatory press release11/20/2025, 1:50 PM

Coegin Pharma AB (publ) publishes its quarterly report for the third quarter of 2025

Press release11/14/2025, 1:42 PM

First Follicopeptide® powered product available for consumer pre-orders November 16 - a historic milestone for Coegin Pharma

Press release11/6/2025, 1:45 PM

Coegin introduces new tailor-made Follicopeptide complementary product - launching early 2026

Regulatory press release10/17/2025, 3:05 PM

Coegin Pharma enters collaboration with Hårklinikken - expands Follicopeptide® commercialization with a world renowned hair clinic brand

Press release10/13/2025, 8:02 AM

Coegin Pharma establishes own agile production facility in Denmark - ensuring control, scalability, and cost efficiency for next phase of growth

Regulatory press release9/17/2025, 12:30 PM

Coegin Pharma enters collaboration with Polish distributor Mercapharm - expands Follicopeptide® commercialisation to Poland

Regulatory press release9/10/2025, 1:00 PM

Coegin Pharma enters collaboration with Swedish retailer Gents - kicks off next phase of Follicopeptide commercialisation

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.